iCo Therapeutics Inc.

Recent News

  • iCo Therapeutics Inc. Provides an Update Regarding Oral Amphotericin Study, Marketing and Partnering Activities

    Vancouver, British Columbia--(Newsfile Corp. - October 28, 2019) -  iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company") and its Australian subsidiary, iCo Therapeutics Pty Ltd., today announced several developments related to its wholly-owned oral Amphotericin B (Oral Amp B) asset and current marketing and partnering efforts.Oral Amphotericin ...

    2019-10-28 4:00 PM ET
  • iCo Therapeutics Inc. Provides a Corporate Update

    Vancouver, British Columbia--(Newsfile Corp. - October 22, 2019) -  iCo Therapeutics Inc. ("iCo" or "the Company") (TSXV: ICO) (OTCQB: ICOTF) today announced several corporate developments.iCo has been monitoring a current US court-mandated auction process, with respect to systemic uses of Bertilimumab, previously sublicensed to Immune Pharmaceuticals. On October 21, 2019, ...

    2019-10-22 7:00 AM ET
  • iCo Therapeutics Announces Second Quarter 2019 Financial Results

    Vancouver, British Columbia--(Newsfile Corp. - August 28, 2019) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company"), today reported financial results for the Quarter ended June 30, 2019. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS").Stated Andrew Rae, ...

    2019-08-28 4:00 PM ET
  • iCo Therapeutics Inc. Announces the Issuance of 41,200,000 Units Pursuant to its Non-Brokered Private Placement

    Vancouver, British Columbia--(Newsfile Corp. - August 19, 2019) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company") is pleased to announce that it has issued 41,200,000 units ("Units") pursuant to a non-brokered private placement (the "Private Placement"). The Units were sold at a price of $0.05 ...

    2019-08-19 7:00 AM ET
  • iCo Therapeutics Provides Corporate Update

    Vancouver, British Columbia--(Newsfile Corp. - August 6, 2019) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company"), today provided an update with respect to the Company's clinical and regulatory path for its Oral Amphotericin B (Oral Amp B) candidate. During Q2 2019, iCo submitted a plan and further ...

    2019-08-06 9:45 PM ET
  • iCo Therapeutics Announces AGM Voting Results

    Vancouver, British Columbia--(Newsfile Corp. - June 28, 2019) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company"), today announced the results of voting at its 2019 Annual General Meeting of Shareholders held on June 27, 2019.A total of 20,801,184 common shares were voted in connection with the ...

    2019-06-28 7:00 AM ET
  • iCo Therapeutics Announces First Quarter 2019 Financial Results

    Vancouver, British Columbia--(Newsfile Corp. - May 30, 2019) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company"), today reported financial results for the Quarter ended March 31, 2019. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS").Stated Andrew Rae, President ...

    2019-05-30 3:39 PM ET
  • iCo Therapeutics Announces 2018 Year End Financial Results

    Vancouver, British Columbia--(Newsfile Corp. - April 30, 2019) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company"), today reported financial results for the year ended December 31, 2018. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS").Stated Andrew Rae, President ...

    2019-04-30 5:37 PM ET